Clearmind Medicine Inc. (NASDAQ:CMND) Sees Large Drop in Short Interest

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totaling 3,861 shares, a decrease of 73.9% from the September 30th total of 14,819 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average trading volume of 35,857 shares, the short-interest ratio is presently 0.1 days.

Clearmind Medicine Trading Up 0.5%

Shares of NASDAQ:CMND traded up $0.03 during trading on Wednesday, reaching $6.00. 5,023 shares of the company were exchanged, compared to its average volume of 111,727. The business’s fifty day simple moving average is $8.62 and its 200-day simple moving average is $52.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.31 and a quick ratio of 4.31. Clearmind Medicine has a 12-month low of $5.25 and a 12-month high of $3,840.00. The firm has a market capitalization of $3.04 million, a PE ratio of -0.02 and a beta of 0.93.

Clearmind Medicine (NASDAQ:CMND) last issued its earnings results on Thursday, September 10th. The company reported ($4.56) earnings per share for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors.

Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns.

Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly.